Glossary | EUPATI Open Classroom

Browse the glossary using this index

Special | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL

J

Japan Pharmaceutical Manufacturers Association

Japan Pharmaceutical Manufacturers Association http://www.jpma.or.jp"

Javna Agencija RS za zdravila in Medicinske Pripomočke

Slovenian National Competent Authority. http://www.jazmp.si/en/"

Joint Clinical Assessment (JCA)

The JCA is the scientific compilation and the description of a comparative analysis of the available clinical evidence on a health technology in comparison with one or more other health technologies or existing procedures – the full definition is provided under Chapter I Article 2 (6) in the HTAR 2021/2282. Available at: Publications Office (europa.eu)

Joint Clinical Assessments (Art. 7–15): A Joint Clinical Assessment (JCA) of a health technology involves a comparative analysis of available clinical evidence on the health technology in comparison with other health technologies or existing procedures. (Art. 7–15) Available at: Regulation - 2021/2282 - EN - EUR-Lex (europa.eu)

Joint Scientific Consultation (JSC)

Joint Scientific Consultations (Art. 16–21): A Joint Scientific Consultation (JSC) aims to advice the Health Technology Developer on evidence likely to be required in a subsequent Joint Clinical Assessment of a health technology.

Health technologies eligible for joint scientific consultations are those for which a joint clinical assessment hasn't been planned but are likely candidates. These consultations occur at the request of the developer.